Sex‐related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study
- 6 May 2016
- journal article
- research article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 89 (4) , 629-637
Abstract
Background: Young women undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) experience greater adverse events than men, potentially due to under‐treatment. We sought to compare the 1‐year outcomes by sex in patients ≤55 years of age from a contemporary PCI cohort.Methods: PROMETHEUS was a retrospective multicenter observational US study comparing outcomes in clopidogrel and prasugrel treated patients following ACS PCI. MACE was defined as a composite of death, myocardial infarction, stroke or unplanned revascularization. Clinically significant bleeding was defined as bleeding requiring transfusion or hospitalization. Hazard ratios were generated using multivariable Cox proportional hazards regression.Results: The study cohort included 4,851 patients of which 1,162 (24.0%) were women and 3,689 (76.0%) were men. In this cohort, the prevalence of diabetes (41.0 vs. 27.9%) and chronic kidney disease (12.7 vs. 7.2%) was higher among women compared with men. Irrespective of sex, prasugrel was used in less than one‐third of patients (31.8% in men vs. 28.1% in women, P = 0.01). Unadjusted, 1‐year MACE (21.1% vs. 16.2%, P < 0.001) and bleeding (3.6% vs. 2.2%, P = 0.01) was significantly higher in women compared with men, but these results were no longer significant after adjustment for risk (HR 1.13, 95% CI 0.94–1.36 for MACE and HR 1.31, 95% CI 0.85–2.04 for bleeding).Conclusion: Women ≤ 55 years of age undergoing ACS PCI have significantly greater comorbidities than young men. Despite a higher risk clinical phenotype in women, prasugrel use was significantly lower in women than men. Female sex was associated with a significantly higher risk of 1‐year MACE and bleeding than male sex, findings that are attributable to baseline differences.Keywords
Funding Information
- Eli Lilly and Company
This publication has 20 references indexed in Scilit:
- Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting StentsJACC, 2016
- Sex‐based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: Three year results from the HORIZONS‐AMI trialCatheterization and Cardiovascular Interventions, 2014
- An Updated Bleeding Model to Predict the Risk of Post-Procedure Bleeding Among Patients Undergoing Percutaneous Coronary InterventionJACC: Cardiovascular Interventions, 2013
- Development and Validation of a Stent Thrombosis Risk Score in Patients With Acute Coronary SyndromesJACC: Cardiovascular Interventions, 2012
- Impact of Bleeding on Mortality After Percutaneous Coronary InterventionJACC: Cardiovascular Interventions, 2011
- Gender differences in coronary heart diseaseNetherlands Heart Journal, 2010
- Contemporary Mortality Risk Prediction for Percutaneous Coronary InterventionJACC, 2010
- The Relationship and Threshold of Stent Length With Regard to Risk of Stent Thrombosis After Drug-Eluting Stent ImplantationJACC: Cardiovascular Interventions, 2010
- The joint contribution of sex, age and type of myocardial infarction on hospital mortality following acute myocardial infarctionHeart, 2009
- Sex Differences in Mortality After Myocardial InfarctionArchives of internal medicine (1960), 1998